Skip to main
PTGX
PTGX logo

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 53%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc. showcases a promising financial outlook, underpinned by an increased EV/Sales multiple of 9.5x, reflecting the company's growth potential bolstered by anticipated milestone payments and royalties contributing to high margins. Market penetration projections for its drug icotrokinra have been raised, estimating a peak unadjusted revenue of $3.2 billion in psoriasis and $3 billion in ulcerative colitis, indicating a significant increase in market expectations. Additionally, the potential clinical success of pipeline candidates, including preclinical assets, could further enhance share value and market position as they are explored across various indications.

Bears say

Protagonist Therapeutics Inc faces significant challenges that contribute to a negative outlook for its stock, primarily due to potential delays or rejections of pipeline asset approvals, which could substantially reduce future cash flows and negatively affect share price. Additionally, ongoing net losses are anticipated until product approval and commercialization, necessitating further capital raises that may dilute shareholder value. The company also encounters regulatory risks and difficulties in patient recruitment for trials, which may jeopardize the timely progress and success of its drug candidates.

Protagonist Therapeutics (PTGX) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 19 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.